This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

PDL BioPharma President Presents At Goldman Sachs Annual Global Healthcare Conference (Transcript)

Stocks in this article: PDLI

PDL BioPharma (PDLI)

Goldman Sachs 33rd Annual Global Healthcare Conference

June 7, 2012

Executives

John McLaughlin - President & CEO

Analysts

Sapna Srivastava - Goldman Sachs

Presentation

Sapna Srivastava - Goldman Sachs

Good morning and thanks for joining us. I'm Sapna Srivastava, Biotech analyst at Goldman Sachs. And it's my pleasure to host John McLaughlin from PDLI to be here. And before we start, I'm required to read this out loud. We are required to make certain disclosures on public appearances about Goldman Sachs relationship with companies that we discuss. The disclosures are related to (inaudible) banking relationships, conferences, compensation received or one person or more ownership. I'm prepared to read disclosures if anyone would like me to. However, these disclosures are available in our most recent report available to you as clients on (inaudible). In view of this non-Goldman Sachs personnel may not represent the company views.

Staying with that, I'll just it off. I guess the one thing I'll start off with, John, is just like you've been with the company and really seen the transition of taking it – somehow taking it apart, breaking apart the company to create shareholder value. Can you help us describe the (inaudible) which led to it and how effective do you think that value creation has been?

John McLaughlin

So, the thought process behind it was that there was a sizable royalty stream and there was an R&D operation and that they weren't being appropriately valued. And so we went through the exercise of splitting the company in two. We spun off the R&D operation (inaudible) Biotech. The royalty operation maintained the name PDL BioPharma. And if you look at the time of the split off both were trading someplace around $10 a share. Subsequent to the split off both were trading someplace – one was around $7 or $8 a share and the other was trading around $10 to $12 a share. And in fact the fastest piece of the operation eventually sold for around $27 a share.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,651.86 +294.99 1.70%
S&P 500 2,048.61 +35.72 1.77%
NASDAQ 4,732.3450 +88.0330 1.90%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs